TKNO

Teknova is a specialty life-science reagent maker whose story is 'the losses are shrinking' — and they genuinely are: FY2025 net loss of -$17.3M is less than half the -$47.5M of FY2022, gross profit jumped +85.9% YoY, and gross margin recovered to 33.2%. That operating leverage is real and is the bull case. But strip away the trajectory and the base business is not growing: revenue has round-tripped from $36.9M (2021) to $41.4M (2022) back to $40.5M (2025), a ~2%/yr CAGR that does not support a growth multiple.

The disqualifying issue is liquidity. The company ended FY2025 with just $5.91M of cash — even after a 59% increase — against operating cash burn of -$8.65M. Cash on hand is smaller than one year of burn, and long-term debt grew 39% to $13.1M. Management's own 10-K forward-looking language lists 'our recent history of losses and our ability to continue as a going concern' and 'our ability to obtain capital on favorable terms, or at all,' alongside repeated references to 'future use of equity or debt financings.' Translation: a capital raise is likely, and with the stock near the low end of its range at $5.79, any equity issuance is dilutive to existing holders. The healthy-looking 4.6x current ratio and 0.51x liabilities/equity mask the fact that the cash line specifically is thin.